Avatrombopag: all 51 studies that test it

Page 1 of 1. Open to participants first (12), then studies with results posted, then the rest; newest registration first within each.

• A Study of Avatrombopag in Adults With Aplastic Anemia Who Did Not Respond to, Cannot Receive, or Had Return of Disease After Standard TreatmentNot yet recruitingNCT07786922Phase 2/3
• Avatrombopag Combined With All-trans Retinoic Acid in the Treatment of Primary Immune ThrombocytopeniaNot yet recruitingNCT07278908Phase 2/3
• Exploring the Efficacy, Safety of a Modified Starting Dosage of Avatrombopag in Immune Throbocytopenia (ITP) - a Pilot StudyRecruitingNCT07133659Phase 4
• The Holistic StudyNot yet recruitingNCT07051915Phase 3
• Avatrombopag in the Treatment of Pediatric Immune ThrombocytopeniaRecruitingNCT06281327Phase 2
• Efficacy and Safety of Avatrombopag vs. Avatrombopag Combined With rhTPO in the Treatment of SAANot yet recruitingNCT06254287Phase 2
• Efficacy and Safety of Avatrombopag in the Treatment of Thrombocytopenia After Haplo-HSCTRecruitingNCT06202625Phase 2/3
• Efficacy and Safety of CsA+AVA in the Treatment of NSAA in the ElderlyRecruitingNCT06004752Phase 2
• Avatrombopag for HCC Patients With Thrombocytopenia Who Intend to Undergo TACE and/or HAICRecruitingNCT06001567Phase 2
• The Safety and Efficacy Study of Avatrombopag Switch in TPO-RA Refractory AARecruitingNCT05518331Not applicable
• Avatrombopag for Chemotherapy-induced ThrombocytopeniaRecruitingNCT05218226Phase 2
• Avatrombopag in the Treatment of Adult Immune Thrombocytopenia With AutoantibodiesRecruitingNCT04993885Phase 2
• Evaluation of Avatrombopag for the Treatment of Thrombocytopenia in Japanese Adults With Chronic ITPCompletedNCT05369208Phase 3Results posted
• Safety and Treatment Satisfaction in Adults With Chronic ITP After Switching to Avatrombopag From Eltrombopag or RomiplostimCompletedNCT04638829Phase 4Results posted
• Avatrombopag for the Treatment of Thrombocytopenia in Pediatric Subjects With Immune Thrombocytopenia for ≥6 MonthsCompletedNCT04516967Phase 3Results posted
• Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Active Non-Hematological CancersCompletedNCT03471078Phase 3Results posted
• Avatrombopag for the Treatment of Thrombocytopenia in Adults Scheduled for a Surgical ProcedureTerminatedNCT03326843Phase 3Results posted
• A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Once-daily Oral Avatrombopag in Japanese Subjects With Chronic Liver Diseases and ThrombocytopeniaCompletedNCT02227693Phase 2Results posted
• Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing an Elective ProcedureCompletedNCT01976104Phase 3Results posted
• Treatment of Thrombocytopenia in Patients With Chronic Liver DiseaseUndergoing an Elective ProcedureCompletedNCT01972529Phase 3Results posted
• Efficacy and Safety of Oral E5501 Plus Standard of Care for the Treatment of Thrombocytopenia in Adults With Chronic Immune Thrombocytopenia (Amendment 02)CompletedNCT01438840Phase 3Results posted
• A Phase 3, Multicenter, Randomized, Double-blind,Active-controlled, Parallel-group Trial With an Open-labelExtension Phase to Evaluate the Efficacy and Safety of OralE5501 Versus Eltrombopag, in Adults With Chronic ImmuneThrombocytopenia (Idiopathic Thrombocytopenic Purpura)TerminatedNCT01433978Phase 3Results posted
• Chronic Hepatitis C Virus Related Thrombocytopenia to Evaluate the Effects of E5501CompletedNCT01355289Phase 2Results posted
• Once-Daily Oral Avatrombopag Tablets Used in Subjects With Chronic Liver Diseases and Thrombocytopenia Prior to Elective Surgical or Diagnostic ProceduresCompletedNCT00914927Phase 2Results posted
• Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With ChronicITP Who Completed 28 Days of Study Treatment in Protocol 501-CL-003CompletedNCT00625443Phase 2Results posted
• Study of AKR-501 Tablets Taken Orally Once Daily for 28 Days in Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP)CompletedNCT00441090Phase 2Results posted
• Avatrombopag vs. Placebo for CIT in GI MalignanciesCompletedNCT05772546Phase 2
• Avatrombopag Combined With IST as First-line Treatment for SAAStatus unknownNCT05720234Phase 2
• Efficacy and Safety of Avatrombopag Combined With IST for the Treatment of HAAA and SAA With Abnormal Liver FunctionStatus unknownNCT05571332Not applicable
• Efficacy and Safety of CSA and Avatrombopag for the Treatment of SAA in the ElderlyStatus unknownNCT05433922Not applicable
• Efficacy and Safety of Avatrombopag for Treating TCP in HBV-ACLF Patients Receiving ALSS TreatmentStatus unknownNCT05382013Phase 4
• Avatrombopag to Promote Platelet Engraftment After Allo-HSCTStatus unknownNCT05143892Phase 2
• Open-Label Study to Evaluate the Safety and Efficacy of Avatrombopag and Remission Rates in Adults With ITP of ≤6 MonthsWithdrawnNCT05046327Phase 3
• Study of Avatrombopag for Temozolomide-induced Thrombocytopenia in Glioma (APATIT-G)WithdrawnNCT04931849Early Phase 1
• Efficacy of Avatrombopag in Thrombocytopenic Patients With Chronic Liver Disease Undergoing an Elective ProcedureStatus unknownNCT04915287Phase 4
• Avatrombopag in Patients With End-stage Liver Disease and ThrombocytopeniaStatus unknownNCT04906083Phase 4
• Efficacy and Safety of Avatrombopag in Cancer Patients With ThrombocytopeniaStatus unknownNCT04896528Phase 2
• Avatrombopag for the Primary Prevention of Thrombocytopenia Induced by Cytarabine-based Chemotherapy in Patients With LymphomaStatus unknownNCT04797182Phase 2
• Avatrombopag Usage in NSAAStatus unknownNCT04728789Phase 2/3
• Avatrombopag on the Treatment of Thrombocytopenia Induced by Chemotherapy of Malignant TumorsCompletedNCT04609891Not applicable
• Avatrombopag for Thrombocytopenia in People With CancerWithdrawnNCT04437953Phase 2
• Avatrombopag for the Treatment of Thrombocytopenia After Donor Hematopoietic Stem Cell TransplantWithdrawnNCT04312789Phase 2
• Study to Assess Pharmacokinetic Drug-Drug Interaction Between Avatrombopag When Co-Administered With Fluconazole, Itraconazole, or Rifampin in Healthy SubjectsCompletedNCT02809768Phase 1
• A Five-Treatment-Period Study to Evaluate the Single-Dose Pharmacokinetics and Pharmacodynamics of Avatrombopag in Healthy Japanese and White SubjectsCompletedNCT02039076Phase 1
• A Single-dose Study in Healthy Japanese Male Adults to Evaluate Pharmacokinetics and Pharmacodynamics of E5501 5 mg Tablet (Study E5501-J081-015)CompletedNCT01774773Phase 1
• A Open-label, Three-period, Partial-replicate Design Study to Evaluate the Inter- and Intrasubject Variability of the Avatrombopag To-be-marketed Formulation Administered as Single Doses of 40 mg to Healthy Subjects Receiving a Low-fat MealCompletedNCT01759394Phase 1
• Pharmacokinetic and Pharmacodynamic Study in Healthy Subjects Comparing the Interactions Between E5501 and Verapamil and Cyclosporine.CompletedNCT01437384Phase 1
• Subject Variability in Two Lots of E5501 Administered to Fed and Fasted Healthy SubjectsCompletedNCT01327872Phase 1
• A Study to Evaluate the Relative Bioavailability and Intra-Subject Variability of Two Lots of E5501 40 mg Tablets Administered Twice as Single Oral Doses to Healthy SubjectsCompletedNCT01289509Phase 1
• A Single-Center, Open-Label, Randomized, 3-Treatment Crossover Bioavailability Study of Single Oral Doses of E5501 Old Tablet Formulation Under Fasted Conditions and a New Tablet Formulation Under Fed and Fasted Conditions in Healthy SubjectsCompletedNCT01260155Phase 1
• Single and Multiple Dose Asian Bridging StudyCompletedNCT01251731Phase 1

← Avatrombopag overview